Pemafibrate reduces atherosclerosis-induced lipoproteins in hypertriglyceridemia
In the treatment of patients with hypertriglyceridemia, use of the selective PPARα modulator pemafibrate leads to a significant reduction in triglyceride-rich lipoproteins and small dense low-density lipoprotein cholesterol without inducing hepatic and renal damage or rhabdomyolysis, as reported in a study.
